|
octyl beta-D-galactopyranoside
|
DB07924 |
|
|
4-(2-HYDROXYPHENYLSULFINYL)-BUTYLPHOSPHONIC ACID
|
DB07925 |
|
|
N-[3-(N'-HYDROXYCARBOXAMIDO)-2-(2-METHYLPROPYL)-PROPANOYL]-O-TYROSINE-N-METHYLAMIDE
|
DB07926 |
|
|
3-[(4-Carboxy-2-hydroxyphenyl)sulfamoyl]-2-thiophenecarboxylic acid
|
DB07927 |
|
|
N-(2-OXOTETRAHYDROFURAN-3-YL)OCTANAMIDE
|
DB07928 |
|
|
N-(TERT-BUTYL)-3,5-DIMETHYL-N'-[(5-METHYL-2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)CARBONYL]BENZOHYDRAZIDE
|
DB07929 |
|
|
(3R)-3-HYDROXYDODECANOIC ACID
|
DB07930 |
|
|
Hexestrol
|
DB07931 |
[A synthetic estrogen that has been used as a hormonal antineoplastic agent.] |
|
dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate
|
DB07932 |
|
|
Erteberel
|
DB07933 |
[Erteberel is an estrogen receptor beta agonist that has been used in trials studying the treatment of Benign Prostatic Hyperplasia.] |
|
[[CYCLOHEXANESULFONYL-GLYCYL]-3[PYRIDIN-4-YL-AMINOMETHYL]ALANYL]PIPERIDINE
|
DB07934 |
|
|
5-[(5-fluoro-3-methyl-1H-indazol-4-yl)oxy]benzene-1,3-dicarbonitrile
|
DB07935 |
|
|
N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
|
DB07936 |
|
|
2-butoxy-9-(2,6-difluorobenzyl)-N-(2-morpholin-4-ylethyl)-9H-purin-6-amine
|
DB07937 |
|
|
(S)-iclaprim
|
DB07938 |
|
|
N-(3-MERCAPTOPROPANOYL)-D-ALANINE
|
DB07939 |
|
|
Odiparcil
|
DB06609 |
|
|
Tafenoquine
|
DB06608 |
[Tafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group.[A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria.[A35690] Tafenoquine was further developed collaboratively between GlaxoSmithKline and Medicines for Malaria Venture.[A35677] It was FDA approved on July 20, 2018.[L3770]] |
|
Catumaxomab
|
DB06607 |
[Catumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122]. Its market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency. Catumaxumab was approved for market in Canada in May 2012 for the same condition [FDA Label]. It is currently available under the brand name Removab.] |
|
Teplizumab
|
DB06606 |
|
